Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 3/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 6/20 | 0.33 |
| ▸ | NNMT | P40261 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL543721 | 0.78 | HCAR3 (0.35) | — | |
| SCHEMBL24160900 | 0.77 | NCF1 (0.45) | NCF1NUDT1NNMTMAOBHTR6 | |
| SCHEMBL3942677 | 0.76 | NCF1 (0.43) | NCF1NUDT1NNMTMAOBHTR6 | |
| SCHEMBL94534 | 0.76 | NCF1 (0.43) | NCF1NUDT1NNMTMAOBHTR6 | |
| SCHEMBL4637203 | 0.72 | MAP4K4 (0.42) | NUDT1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL19957709 | 0.71 | NCF1 (0.39) | NCF1NUDT1NNMTMAOB | |
| SCHEMBL6679844 | 0.71 | NCF1 (0.39) | NCF1NUDT1NNMTMAOBCYP1A2 | |
| SCHEMBL15920651 | 0.70 | — | — | |
| SCHEMBL24069964 | 0.69 | ALDH1A1 (0.44) | NCF1SCN5ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL28091587 | 0.68 | NCF1 (0.61) | NCF1NNMTMAOBKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| CN-101268038-A | Amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI AVENTIS (FR) | 2008-09-17 | — | — | CN | disclosed |
| EP-1931620-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | Sanofi-Aventis (FR) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007034252-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIQUIDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287434-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | NCF1 378/4885NUDT1 3322/4885NNMT 4018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.